Vicuron completes Phase III anidulafungin enrollment

Vicuron (MICU; NMerc:MICU) completed enrollment of about 250 patients with invasive candidiasis in a double-blind Phase III trial comparing intravenous anidulafungin to intravenous fluconazole for 10-...